Galenical formulations of organic compounds

Galenical formulations of organic compounds

The present invention relates to a pharmaceutical oral fixed dose combination comprising (a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, (b) a therapeutically effective amount of Valsartan, or a pharmaceutically acceptable salt thereof, wherein the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: HIRSCH, STEFAN, ALTENBURGER, RALF, ADLER, SABINE, GHOSH, INDRAJIT, WOLF, MARIERISTINE, TAILLEMITE, JULIEN, WEN, HONG, BABIOLE SAUNIER, MAGGY, KELLER, PATRICE FRANCOIS, LOGGIA, NICOLETTA, KOWALSKI, JAMES, TONG, WEI-QIN, VIPPAGUNTA, SUDHA, MATHARU, AMOL SINGH, BARGENDA, NICOLE, LAKSHMAN, JAY PARTHIBAN, KOCHHAR, CHARU, CURDY, CATHERINE, LI, SHOU-FENG, BOCK, MICHAELA ANNA MARIA, BUSS, BRUNO
Format: Patent
Sprache:chi ; eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention relates to a pharmaceutical oral fixed dose combination comprising (a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, (b) a therapeutically effective amount of Valsartan, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component (a) of 80% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component (b) of 25% or more after 30 minutes, and 40% or more after 60 minutes at Ph 4.5.